Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Vickie Capps
AddedFeb 15, 2024
UpdatedMay 1, 2026
Vickie Capps

Vickie Capps

Board Member, Nuvasive

Vickie Capps's Career

Nuvasive
Nuvasive

San Diego, CA, US

Board Member· Board
Janux Therapeutics
Janux Therapeutics

San Diego, CA, US

Board Member· Board
Omniguide
Omniguide

Lexington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Vickie Capps's Career

Nuvasive
Nuvasive
Acquired$65.3M01997San Diego, CA, US
Board Member· Board

Leadership at Nuvasive

Scott HuennekensScott HuennekensBoard Member
John DeFordJohn DeFordBoard Member
James MarinoJames MarinoCo-Founder
Chris BarryChris BarryCEO
Jim McKinleyJim McKinleyCo-Founder
Greg LucierGreg LucierBoard Member

Similar to Nuvasive

SpineologySpineologySt. Paul Park, MN, USMedical Devicesest. 1997SpineologySt. Paul Park, MN, US · est. 1997

Spineology, Inc.: A US-based producer and distributor of advanced medical instruments for spinal care.

Series A · $28.6M103
Spinal USASpinal USAParsippany-Troy Hills, NJ, USMedical Devicesest. 2005Spinal USAParsippany-Troy Hills, NJ, US · est. 2005

Precision Spine: A US-based global provider of quality spinal products for healthcare professionals.

Angel · $258.4k75
NanovisNanovisWest Lafayette, IN, USMedical Devicesest. 2009NanovisWest Lafayette, IN, US · est. 2009

US-based Nanovis specializes in developing cervical and lumbar interbody fusion devices.

Series A · $9.5M22
Janux Therapeutics
Janux Therapeutics
Public$252.4M702017San Diego, CA, US
Board Member· Board

Leadership at Janux Therapeutics

Alana McNultyAlana McNultyBoard Member
Peter ThompsonPeter ThompsonBoard Member
Sheila GujrathiSheila GujrathiBoard Member
David CampbellDavid CampbellFounder
Dave Campbell [LION] 13,000Dave Campbell [LION] 13,000CEO
Omniguide
Omniguide
Series F$129.8M3752000Lexington, MA, US
Board Member· Board

Leadership at Omniguide

Matt JenningsMatt JenningsBoard Member
Doug KohrsDoug KohrsBoard Member
Nicholas KonidarisNicholas KonidarisBoard Member
Yoel FinkYoel FinkBoard Member
Lisa SuennenLisa SuennenBoard Member
Ray StataRay StataBoard Member

Similar to Omniguide

OmnioxOmnioxSan Carlos, CA, USBiotechest. 2006OmnioxSan Carlos, CA, US · est. 2006

US-based Omniox, a biotech firm, innovates in cancer, cardiovascular disease, and trauma treatment.

Series D · $20.1M7

Vickie Capps's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Vickie Capps

Vikram SudarsanVikram SudarsanBoard Member · Engrail TherapeuticsStephen CunninghamStephen CunninghamBoard Member · Engrail TherapeuticsFred DotzlerFred DotzlerBoard Member · Bayhill TherapeuticsBrian BirkBrian BirkBoard Member · Sun Mountain CapitalCraig EagleCraig EagleBoard Member · Generex BiotechnologyTerry LiermanTerry LiermanBoard Member · Welldoc